ML Bio Solutions - Crunchbase Company Profile & Funding

Overview

ML Bio Solutions

Growth Score

Heat Score

Company Performance Metrics

Score

Trend

About These Metrics

AI Content may contain mistakes and is not legal, financial or investment advice.

Learn more.

Growth Score - The measure of growth based on company activity, operational metrics, and investments

Growth Trend - The change in the growth score over the given time period

Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity

Heat Trend - The change in the heat score over the given time period

Recent Events

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

See more interactive data and historical milestones on desktop for the best experience

About ML Bio Solutions

CB Rank

331396

ML Bio Solutions develops oral treatments for limb girdle muscular dystrophy type 2I (LGMD2I).

Founded

obfuscation

Private

Palo Alto, California, United States

11-50

mlbiosolutions.com

Biotechnology

Health Care

Health Diagnostics

Key People

George McLendon: CEO
Past Role: Rice University, Provost
Luther Lockwood: Founder, Board Chairman and President

Details

Operating Status

Active

Company Type

For Profit

Founders

Luther Lockwood

About the Company

ML Bio Solutions focuses on developing an oral treatment for patients with limb girdle muscular dystrophy type 2I (LGMD2I). The company is working on a therapeutic approach to address the genetic mutations in the FKRP gene, which cause the disease. ML Bio Solutions is part of BridgeBio Pharma and is involved in clinical trials to advance their

treatment options for this rare genetic disorder.

Contact Email

info@mlbiosolutions.com

Predictions & Insights

Growth Prediction

See this Growth Prediction

Products & Services

BBP-418

An investigational oral therapy designed to supplement the missing sugar in muscle cells to restore alpha dystroglycan function in patients with LGMD2I.

LGMD2I Lead-in Study (Natural History Study)

An observational study collecting clinical and biomarker data to understand disease progression and identify endpoints for future clinical trials in LGMD2I patients.